Voices
Evert Van Aken: ESMO-ESTRO Statements on the Safety of Combining Radiotherapy with Immune Inhibitors
Evert Van Aken/LinkedIn

Evert Van Aken: ESMO-ESTRO Statements on the Safety of Combining Radiotherapy with Immune Inhibitors

Evert van Aken, Radiation Oncology Resident at UMC Utrecht, shared a post on LinkedIn about a paper he co-authored published on Annals of Oncology:

“I am pleased to share that our second ESMO-ESTRO publication, presenting multidisciplinary consensus statements on the safety of combining radiotherapy with targeted therapies and immunotherapy, has just been published online in Annals of Oncology!

Special thanks to all collaborators from ESMO and ESTRO!”

Title: ESMO-ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors

Authors: E.S.M. van Aken, B. Devnani, A. Prelaj, L. Castelo-Branco, C.A.M. Marijnen, D. Martins-Branco, M.A. Gambacorta, A. Lamarca, K. Harrington, G. Minniti, M. Hecht, D. Papamichael, M. Krause, R. Cathomas, K. Lindberg, S.M. O’Cathail, U. Nestle, J. Barriuso, S. Nowicki, C. Rödel, P. Boot, C. Belka, U. Ricardi, F. Lordick, D. De Ruysscher, G. Pentheroudakis, M.C. de Jong, A.K. Gandhi

Read the full article on Annals of Oncology.

ESMO-ESTRO
More posts featuring Evert Van Aken on OncoDaily.

A Prelaj A. Lamarca A.K. Gandhi B. Devnani C. Belka C. Rödel C.A.M. Marijnen cancer D. De Ruysscher D. Martins Branco D. Papamichael E.S.M. van Aken ESMO–ESTRO F. Lordick G Pentheroudakis G. Minniti J. Barriuso K. Harrington K. Lindberg L. Castelo-Branco M. Hecht M. Krause M.A. Gambacorta M.C. de Jong OncoDaily Oncology P. Boot R. Cathomas S. Nowicki S.M. O’Cathail U. Nestle U. Ricardi